Exploration of Targeted Anti-tumor Therapy

Table 3

Summary of evidence for most promising methylation biomarkers for diagnosis of CRC in stool (sensitivity > 75%)

Biomarker gene(s)	Test	Sensitivity (%)	Specificity (%)	Reference
APC, ATM, hMLH1, HLTF, MGMT, SFRP2	CRC	75	90	[84]
COL4A2, TLX2	CRC	91	98	[80]
FBN1, SNCA	CRC	84	93	[85]
GATA5	CRC	84	83	[86]
GDNF, SNAP91, NDRG4	CRC	86	96	[28]
HPP1	CRC	100	71	[87]
HPP1, MGMT, SFRP2	Adenoma	94	77	[87]
ITGA4, SFMBT2, THBD, ZNF304	CRC	96	87	[88]
KCNJ12, VAV3-AS1, EVC	CRC	83	71	[88]
NDRG4	CRC	76–98	89	[82, 83, 86]
NDRG4, BMP3	CRC	98	90	[89]
NDRG4, BMP3, mutation KRAS, hemoglobin	CRC	92–98	87–90	[89, 90]
NDRG4, BMP3, mutation KRAS, hemoglobin	Adenoma	82	93	[54]
NEUROD1, FAM72C	CRC	83	77	[88]
MLH1, VIM, MGMT	CRC	75	86.5	[91]
RARB2, p16^INK4a, MGMT, APC	CRC	75	/	[24]
SDC2	CRC	90	89	[51]
SFRP2	Adenoma	76–87	55–100	[9, 52]
SFRP2, TFPI2, NDRG4, BMP3	CRC	94	55	[52]
SEPT9	Adenoma	83	92	[92]
VIM, NDRG4, BMP3, TFPI2	CRC	89	90	[76]
SFRP1	CRC	89	86	[93]
VIM	CRC	38–81	82–95	[94]
VIM	Adenoma	33–83	93–100	[95]
SFRP2, GATA4/5, NDRG4, VIM	CRC	96	65	[96]
TFPI2	Adenoma	81	94	[97]
TFPI2	CRC	76–93	89–100	[97, 98]

Return to article view

ATM: ATM serine/threonine kinase; hMLH1: homo sapiens DNA mismatch repair; HLTF: helicase like transcription factor; GATA5: GATA binding protein 5; HPP1: hyperpigmentation progressive 1; SFMBT2: Scm like with four mbt domains 2; THBD: thrombomodulin; VAV3-AS1: VAV3 antisense RNA 1; EVC: EvC ciliary complex subunit 1; NEUROD1: neuronal differentiation 1; FAM72C: family with sequence similarity 72 member C; MLH1: MutL homolog 1